Clinical trials: Head or Neck Cancer
Hodgkin Lymphoma, Non Hodgkin Lymphoma
124I-FIAU Imaging in EBV and KSHV Associated Cancers
This research is being done to determine whether viral thymidine kinase (TK) expression in Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) virus-associated tumors is sufficient to image.
- Conditions
- Hodgkin Lymphoma, Non Hodgkin Lymphoma, Kaposi's Sarcoma, Gastric Cancer
- Trial name
- NCT00982449
- Testing
- FIAU-PET-CT-2, FIAU-PET-CT-4
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Cancer
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles.
- Trial name
- NCT00603915
- Testing
- Gemcitabine, Carboplatin/Cisplatin, erlotinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
This study was a multi-center, single-arm, open-label phase II clinical trial. Thirty patients with unresectable locally advanced or postoperative recurrent esophageal squamous cell carcinoma were treated with concurrent…
- Trial name
- NCT06885814
- Testing
- Adebrelimab: 1200 mg day1, Q3W, 3 times
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
This phase I trial is studying the side effects and best dose of gefitinib when given together with radiation therapy with or without cisplatin in treating patients with stage III or stage IV head and neck cancer.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00033449
- Testing
- gefitinib, radiation therapy, cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Advanced MRI Sequences for Radiation Therapy Treatment Planning
The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment planning or treatment follow-up MRI.
- Trial name
- NCT02340715
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Medical College of Wisconsin
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT02559687
- Testing
- pembrolizumab
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Non Small Cell Lung Cancer
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- CHECK'UP (NCT03412058)
- Testing
- Biopsy
- Where
- 19 sites in France
- Volunteers
- 152 people
- Sponsor
- UNICANCER
Head and Neck Cancer
Preventing Lymphedema in Patients Undergoing Surgical Treatment for Head and Neck Cancer Through Vein Reconstruction
The goal of this clinical trial is to learn if facial vein reconstruction after neck dissection works to reduce rates of lymphedema in adults getting surgical treatment for head and neck cancer.
- Trial name
- NCT07694726
- Testing
- Facial Vein Reconstruction
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Pittsburgh
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Esophagus Cancer, Esophagogastric Junction Cancer
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
Ratiotherapy alone is the current standard treatment for elderly esophageal or esophagogastric cancer in China. And Little is known about chemoradiotherapy (CRT) in elderly patients.
- Conditions
- Esophagus Cancer, Esophagogastric Junction Cancer, Radiotherapy; Complications, Chemoradiation
- Trial name
- NCT02979691
- Testing
- SIB-IMRT, S-1
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Cancer
A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell…
- Trial name
- NCT00995358
- Testing
- peptide
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
Esophageal Cancer
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00655876
- Testing
- cetuximab, cisplatin, paclitaxel
- Where
- 175 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01487733
- Testing
- gene expression analysis, in situ hybridization, immunohistochemistry staining method
- Volunteers
- 155 people
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.